Apogee Therapeutics Announces Upsized $345.1 Million IPO

San Diego – July 18, 2023 – Cooley advised the underwriters in the upsized $345.1 million initial public offering of Apogee Therapeutics, a biotechnology company. Partners Div Gupta, Charlie Kim and Kristin VanderPas led the Cooley team advising the underwriters.

Apogee sold 20,297,500 shares of its common stock at a public offering price of $17 per share, less underwriting discounts and commissions, including full exercise of the underwriters’ option to purchase 2,647,500 additional shares. Apogee’s stock began trading on July 14, 2023, under the ticker symbol APGE on the Nasdaq Global Market.

Jefferies, TD Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Wedbush PacGrow acted as lead manager for the offering.

As of the closing date of this IPO, Cooley worked on four of five US biotechnology IPOs raising at least $20 million in 2023.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.